00:04 , Apr 6, 2019 |  BioCentury  |  Finance

Everybody up

Biotech stocks were off to a strong start in 1Q19, with 71% of companies tracked by BioCentury seeing market cap growth in the quarter. Across all market cap bands, biotechs saw a median gain of...
21:05 , Mar 25, 2019 |  BC Extra  |  Clinical News

Avanir's AVP-786 meets in Phase III for Alzheimer's agitation

Avanir said one of two doses of AVP-786 met the primary endpoint of improving agitation symptoms in the Phase III 15-AVP-786-301 trial to treat agitation in patients with Alzheimer's dementia. AVP-786 comprises deuterium-modified dextromethorphan --...
04:15 , Mar 23, 2019 |  BioCentury  |  Product Development

Baby steps beyond beta amyloid

Companies are taking steps -- baby steps -- to test new targets in pathways such as neuroinflammation and neuroprotection as a means to treat Alzheimer’s disease. The failure of aducanumab won’t be the final nail...
00:02 , Mar 7, 2019 |  BC Extra  |  Clinical News

Allergan's rapastinel misses as adjunct depression therapy

Allergan said late Wednesday that rapastinel as adjunctive therapy missed the primary endpoint in three Phase III trials for the acute treatment of major depressive disorder (MDD). Allergan plc (NYSE:AGN) is also conducting a Phase...
20:33 , Feb 5, 2019 |  BC Extra  |  Company News

FDA psychiatry product division director joins Allergan

Following a 12-year tenure as director of FDA’s Division of Psychiatry Products, Mitchell Mathis has joined Allergan plc (NYSE:AGN) as CMO for CNS products. Mathis left FDA on Jan. 19 and joined Allergan later in...
19:52 , Feb 1, 2019 |  BC Week In Review  |  Financial News

Drug delivery company Lyndra raises $55M series B

Lyndra Therapeutics Inc. (Watertown, Mass.) raised $55 million in a series B round to advance compounds delivered via its capsule platform. Polaris Partners led the round and was joined by all other original investors and...
12:04 , Jan 29, 2019 |  BC Extra  |  Financial News

Drug delivery company Lyndra raises $55M series B

Lyndra Therapeutics Inc. (Watertown, Mass.) raised $55 million in a series B round to advance compounds delivered via its capsule platform. Polaris Partners led the round and was joined by all other original investors and...
18:43 , Jan 18, 2019 |  BC Week In Review  |  Clinical News

Aptinyx's pain compound misses Phase II endpoint

Aptinyx Inc. (NASDAQ:APTX) said all three doses of NYX-2925 missed the primary endpoint in a Phase II trial to treat pain associated with diabetic peripheral neuropathy. The primary endpoint measured mean change in average daily...
18:36 , Jan 16, 2019 |  BC Extra  |  Clinical News

Aptinyx tumbles after pain compound misses Phase II endpoint

Aptinyx Inc. (NASDAQ:APTX) lost $11.85 (66%) to $5.98 Wednesday after it said all three doses of NYX-2925 missed the primary endpoint in a Phase II trial to treat pain associated with diabetic peripheral neuropathy. The...
17:47 , Jan 11, 2019 |  BC Week In Review  |  Clinical News

Axsome's AXS-05 meets in Phase II for MDD

Axsome Therapeutics Inc. (NASDAQ:AXSM) added $4.24 (161%) to $6.87 on Jan. 7 after reporting that AXS-05 met the primary endpoint in the Phase II ASCEND trial to treat moderate-to-severe major depressive disorder (MDD). On the...